Latest Period
Q2 2026
Security Snapshot
Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT) Institutional Ownership
CUSIP: 67080T108
13F Institutional Holders and Ownership History from Q1 2022 to Q2 2026
Institutions Reporting
82
Shares (Excl. Options)
10,235,644
Price
$18.39
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- NVCT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 10,235,644
- Total 13F value
- $188,754,502
- Portfolio coverage rank
- 0%
- Share change
- +5,723,016
- Value change
- +$105,655,568
- Number of holders
- 82
- Shares outstanding
- 32,314,196
- SEC-reported price per share
- $22.76
- Insider filing price
- $22.76
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NVCT - Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 67080T108.
- 82 institutions reported positions in Q2 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 62 to 82 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $34,936,893 to $188,754,502.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 82 institutions filings for Q2 2026.
Security key
67080T108
Latest holder period
Q2 2026
13F holders
82
13D/G owners
1
CIK / CUSIP context first
Open Q2 2026 holders
NVCT full holder history
Nuvectis Pharma, Inc. SEC filings
Nuvectis Pharma, Inc. company facts
Nuvectis Pharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080T108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
NVCT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. | 5.1% | $30,389,563 | 1,648,024 | Soleus Capital Management, L.P. | 04 Aug 2026 |
As of 30 Jun 2026, 82 institutional investors reported holding 10,235,644 shares of Nuvectis Pharma, Inc. - Common Stock, par value $0.00001 per share (NVCT). This represents 32% of the company’s total 32,314,196 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
30%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 4.8% | 1,550,000 | 1.3% | $28,504,500 | |
| BlackRock, Inc. | 3.1% | 1,001,285 | +31% | 0% | $18,413,632 |
| PERCEPTIVE ADVISORS LLC | 3.1% | 1,000,000 | 0.29% | $18,390,000 | |
| Soleus Capital Management, L.P. | 3.1% | 1,000,000 | 0.63% | $18,390,000 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 872,482 | +32% | 0% | $16,044,944 |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 2.4% | 777,078 | +19% | 4.9% | $14,290,464 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 432,273 | +13% | 0% | $7,951,022 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.2% | 382,945 | 1% | $7,042,359 | |
| BALDWIN WEALTH PARTNERS LLC/MA | 1.2% | 382,015 | +0.9% | 0.46% | $7,025,256 |
| Occam Crest Management LP | 1.1% | 357,147 | -12% | 4.1% | $7,389,371 |
| Alyeska Investment Group, L.P. | 0.85% | 275,000 | 0.01% | $5,057,250 | |
| STATE STREET CORP | 0.77% | 248,198 | +49% | 0% | $4,564,361 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.67% | 217,286 | +106% | 0% | $3,995,890 |
| Avidity Partners Management LP | 0.62% | 200,000 | 0.59% | $3,678,000 | |
| NORTHERN TRUST CORP | 0.45% | 146,714 | +18% | 0% | $2,698,071 |
| VANGUARD FIDUCIARY TRUST CO | 0.39% | 127,554 | +11% | 0% | $2,345,718 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.37% | 118,297 | +28% | 0% | $2,175,482 |
| CITADEL ADVISORS LLC | 0.36% | 115,532 | +47% | 0% | $2,124,633 |
| Kalehua Capital Management LLC | 0.31% | 100,000 | 1.1% | $1,839,000 | |
| OPPENHEIMER & CO INC | 0.23% | 73,566 | 0% | 0.01% | $1,352,879 |
| UBS Group AG | 0.21% | 69,200 | +79% | 0% | $1,272,588 |
| CIBC Bancorp USA Inc. | 0.2% | 66,211 | +166% | 0% | $900,301 |
| FORBES J M & CO LLP | 0.18% | 59,000 | 0% | 0.09% | $1,085,010 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.18% | 57,133 | +15% | 0% | $1,050,676 |
| Informed Momentum Co LLC | 0.15% | 47,168 | 0.08% | $867,420 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
18
Latest
Q2 2026
Rows shown
1-18 of 18
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 10,235,644 | $188,754,502 | +$105,655,568 | $18.39 | 82 |
| 2026 Q1 | 4,519,840 | $34,936,893 | +$2,076,848 | $7.73 | 62 |
| 2025 Q4 | 4,238,693 | $32,029,225 | +$4,308,822 | $7.55 | 47 |
| 2025 Q3 | 3,694,801 | $22,240,671 | +$875,366 | $6.02 | 52 |
| 2025 Q2 | 3,242,656 | $24,212,274 | +$8,414,990 | $7.47 | 46 |
| 2025 Q1 | 2,047,125 | $20,049,463 | +$7,527,323 | $9.77 | 33 |
| 2024 Q4 | 1,320,778 | $7,145,290 | +$1,393,786 | $5.41 | 31 |
| 2024 Q3 | 1,049,389 | $6,599,330 | -$771,215 | $6.29 | 31 |
| 2024 Q2 | 1,205,075 | $7,627,698 | -$2,433,916 | $6.33 | 40 |
| 2024 Q1 | 1,561,977 | $12,807,385 | +$393,490 | $8.20 | 40 |
| 2023 Q4 | 1,513,319 | $12,620,464 | +$1,886,095 | $8.34 | 36 |
| 2023 Q3 | 1,277,304 | $16,463,587 | +$85,915 | $12.89 | 33 |
| 2023 Q2 | 1,252,927 | $20,033,227 | +$12,444,259 | $15.97 | 37 |
| 2023 Q1 | 483,928 | $6,343,634 | -$3,188,708 | $13.11 | 13 |
| 2022 Q4 | 983,925 | $7,378,970 | +$968,656 | $7.50 | 11 |
| 2022 Q3 | 1,417,003 | $10,047,000 | +$5,345,357 | $7.09 | 9 |
| 2022 Q2 | 643,014 | $7,201,000 | +$370,284 | $11.20 | 10 |
| 2022 Q1 | 628,110 | $4,654,000 | +$4,654,000 | $7.40 | 7 |